Title
Does anandamide elevation in cerebrospinal fluid protect against transition into frank psychosis?

Permalink
https://escholarship.org/uc/item/7x04m1fv

Authors
Koethe, D
Giuffrida, A
Schreiber, D
et al.

Publication Date
2008-08-01

DOI
10.1016/S0924-977X(08)70706-5

License
CC BY 4.0

Peer reviewed
**P.3.f Psychotic disorders and antipsychotics – Other (basic)**

**P.3.f.001** Does anandamide elevation in cerebrospinal fluid protect against transition into frank psychosis?

D. Koethe\(^1\), A. Giuffrida\(^2\), D. Schreiber\(^3\), M. Hellmich\(^3\), F. Schultz-Lutter\(^1\), S. Ruhrmann\(^1\), J. Klosterkötter\(^3\), D. Piomelli\(^4\), F.M. Leweke\(^1\).

1University of Cologne, Psychiatry and Psychotherapy, Cologne, Germany; 2University of Texas Health Science Center, Department of Pharmacology, San Antonio, USA; 3University of Cologne, Institute of Medical Statistics Informatics and Epidemiology, Cologne, Germany; 4University of California, Department of Pharmacology, Irvine, USA

Endocannabinoids are a family of bioactive lipids that bind to cannabinoid receptors in the brain. As in schizophrenia, they play a homeostatic role for the endocannabinoid lipid Anandamide (AEA) was suggested, we investigated patients suffering of initial prodromal stage (IPS) of schizophrenic psychosis, which is defined as an early disease stage prior to the onset of frank psychosis (for review see [1]).

We measured the levels of the endogenous cannabinoid AEA, and its structural analog oleoylethanolamide (OEA) in cerebrospinal fluid (CSF) and serum of IPS (n = 27) patients alongside healthy volunteers (HC; n = 81) by HPLC/MS [2]. An IP was assumed if any of ten cognitive-perceptive basic symptoms or any attenuated or any transient psychotic symptom was present. Lumbar puncture took place shortly after the first visit in the Cologne Early Recognition and Intervention Centre for mental disorders. The cumulative probability of no transition into frank psychosis was estimated by the Kaplan-Meier method and compared between groups. The relative risk of transition of the high vs low group was estimated by the log rank test (hazard ratio). We found that AEA increases were found in CSF exclusively, while neither AEA nor OEA in both body fluids were altered. Levels in CSF of IPS patients were significantly elevated, while those in HC were not.

In IPS patients we found a trend for the elevation of AEA in CSF to be associated with extended time of transition into frank psychosis (p = 0.095) during an observational period of at least 45 months after initial investigation, calculated by splitting patients at the median CSF AEA value (0.006 pmol/ml) into low and high groups. The relative risk of transition of the high vs low group was 0.33 (95% confidence interval 0.09 to 1.29).

Our data provide further support for the hypothesis of an adaptive or potentially protective role for the endocannabinoid system in early schizophrenia. The AEA elevation was comparable to that found by Giuffrida et al. [3] in first-onset, antipsychotic-naive schizophrenia. AEA increase was found in CSF exclusively, making its central origin most likely. The longer transition time into frank psychosis in IPS patients showing an AEA elevation is in line with our hypothesis of an adaptive role of the endocannabinoid system in psychosis. As the anandamidergic dysregulation is already manifest in the prodromal course of the disease it emphasizes the importance of longitudinal studies to improve our understanding of endocannabinoidergic function in early schizophrenia and may lead to new pharmacological treatment strategies.

Table 1: Demographic and clinical characteristics of participants

<table>
<thead>
<tr>
<th>Age, years; median (25th to 75th percentile)</th>
<th>Initial prodromal stage (n=27)</th>
<th>Healthy controls (n=81)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex, male; n (%)</strong></td>
<td>19 (70.4)</td>
<td>45 (55.6)</td>
</tr>
<tr>
<td><strong>Body mass index; mean (SD)</strong></td>
<td>22.70 (± 2.55)</td>
<td>23.13 (± 3.29)</td>
</tr>
<tr>
<td><strong>Nicotine use; n (%)</strong></td>
<td>7 (70%)</td>
<td>35 (43.8)</td>
</tr>
<tr>
<td><strong>Cannabis use; n (%)</strong></td>
<td>9 (33.3)</td>
<td>28 (34.6)</td>
</tr>
<tr>
<td><strong>Never</strong></td>
<td>9 (33.3)</td>
<td>28 (34.6)</td>
</tr>
<tr>
<td><strong>&lt;20 lifetime</strong></td>
<td>7 (25.9)</td>
<td>25 (30.9)</td>
</tr>
<tr>
<td><strong>&gt;20 but &lt;50 lifetime</strong></td>
<td>3 (11.1)</td>
<td>–</td>
</tr>
<tr>
<td><strong>&gt;50 but &lt;100 lifetime</strong></td>
<td>1 (3.7)</td>
<td>–</td>
</tr>
<tr>
<td><strong>&gt;100 but &lt;500 lifetime</strong></td>
<td>7 (25.9)</td>
<td>–</td>
</tr>
</tbody>
</table>

References


**P.3.f.002** CNS infections during childhood and risk for schizophrenia: a case control study

D. Halperin\(^1\)*, M. Davidson\(^1\), N. Werbeloff\(^2\), R. Yoffe\(^2\), A. Levine\(^3\), G. Livni\(^4\), M. Weiser\(^5\).

1Chaim Sheba Medical Center, Psychiatry, Tel Hashomer, Israel; 2Israeli Ministry of Health, Ministry of Health, Jerusalem, Israel; 3Wolfson Medical Center, Psychiatry, Holon, Israel; 4Schneider Children’s Medical Center, Pediatrics, Petah Tikwa, Israel; 5Sheba Medical Center, Psychiatry, Tel Hashomer, Israel

**Purpose of the study:** The aim of this study was to assess the risk for schizophrenia after a viral or bacterial CNS infection during childhood, through a large case control study.

**Introduction:** Some studies found a positive association between viral or bacterial CNS infections during childhood and risk for later schizophrenia, psychotic disorder or mood disorder with psychotic symptoms [1,2]. A study conducted to evaluate the influence of viral CNS infection on later risk for schizophrenia could not confirm these results [3]. A large, recently published Swedish study found a slightly increased risk for nonaffective psychotic illness and schizophrenia with previous viral CNS infections, but no increased risk with bacterial infections [2].